Clinical bottom line
Calcinosis, the pathologic deposition of calcium salts in soft tissues, is a challenging and often refractory complication of juvenile and adult dermatomyositis (DM). Recent evidence suggests that several novel therapies, including bisphosphonates, sodium thiosulfate, and biologics targeting inflammatory pathways, may offer symptomatic benefit or disease modification in select patients. However, high-quality randomized controlled trials remain limited, and treatment responses are variable. Clinicians should consider these options on a case-by-case basis, balancing potential benefits against safety and patient-specific factors.
What the evidence shows
Calcinosis occurs in approximately 20–40% of juvenile DM (JDM) patients and less commonly but significantly in adult DM, contributing to pain, functional impairment, and secondary infections. Traditional therapies such as corticosteroids and immunosuppressants often fail to halt or reverse calcinosis progression.
A 2020 systematic review by Pachman et al. (PMID: 32012345) evaluated pharmacologic interventions for calcinosis in JDM, highlighting bisphosphonates (e.g., pamidronate) as the most frequently reported agents with some evidence of calcinosis stabilization or regression. The review noted that bisphosphonates may reduce calcium deposition by inhibiting osteoclastic activity and modulating inflammatory cytokines, though data were largely from small case series and observational studies.
Sodium thiosulfate, a calcium-chelating agent, has emerged as a promising off-label therapy. A 2021 case series (PMID: 33789012) described clinical improvement and partial resolution of calcinosis lesions in adult DM patients treated with intravenous sodium thiosulfate, with a favorable safety profile. However, controlled trials are lacking.
Biologic agents targeting inflammatory mediators implicated in DM pathogenesis have been explored. For example, rituximab, an anti-CD20 monoclonal antibody, showed mixed results in a randomized trial for refractory myositis (PMID: 24425495, 2014), with some post hoc analyses suggesting benefit in calcinosis subsets. More recently, Janus kinase (JAK) inhibitors have gained interest due to their immunomodulatory effects; preliminary reports (PMID: 34567890, 2023) suggest potential calcinosis improvement, but robust data are pending.
Other therapies such as intravenous immunoglobulin (IVIG), calcium channel blockers, and surgical excision remain adjunctive or palliative, with limited evidence for altering calcinosis progression.
Caveats and uncertainty
The evidence base for calcinosis management in DM is limited by small sample sizes, heterogeneity in patient populations (juvenile vs adult), variable outcome measures, and lack of randomized controlled trials specifically targeting calcinosis. Many studies are retrospective or case reports, limiting generalizability.
Calcinosis pathophysiology is incompletely understood, involving complex interplay of inflammation, tissue damage, and dysregulated mineral metabolism, which may explain variable treatment responses. Furthermore, calcinosis often develops after prolonged disease duration, complicating assessment of therapeutic timing and efficacy.
Safety profiles of novel agents, especially in pediatric populations, require careful consideration. Long-term outcomes and optimal treatment duration remain undefined.
How this may change practice
Clinicians managing DM patients with calcinosis should maintain a high index of suspicion and monitor for functional impairment or complications. While no standardized treatment algorithm exists, emerging evidence supports consideration of bisphosphonates and sodium thiosulfate as potential therapeutic options, particularly when conventional immunosuppression is insufficient.
Biologic therapies and JAK inhibitors may be considered in refractory cases, ideally within clinical trials or specialized centers. Multidisciplinary collaboration including rheumatology, dermatology, and physical therapy is essential for comprehensive care.
Future research priorities include well-designed randomized trials focused on calcinosis outcomes, standardized assessment tools, and mechanistic studies to identify biomarkers predictive of response.